Efficacy and Safety of Cevira速 in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)
A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to evaluate efficacy and safety of Cevira速 in patients with cervical histologic high-grade squamous intraepithelial lesions (HSIL).
Cervical Intraepithelial Neoplasia Grade 2/3
COMBINATION_PRODUCT: Cevira速|COMBINATION_PRODUCT: Placebo
The proportion of responders at 6 months after first treatment, A responder is defined as follows:

* Normal histology; or
* LSIL histology and clearance of baseline HPV, 6 months
The proportion of HPV positive patients with clearance of baseline HPV at 6 months after first treatment., The proportion of HPV positive patients with clearance of baseline HPV at 6 months after first treatment., 6 months|The proportion of HPV16 positive patients with clearance of HPV16 at 6 months after first treatment., The proportion of HPV16 positive patients with clearance of HPV16 at 6 months after first treatment., 6 months|The proportion of HPV16 and/or HPV18 positive patients with clearance of baseline HPV at 6 months after first treatment., The proportion of HPV16 and/or HPV18 positive patients with clearance of baseline HPV at 6 months after first treatment., 6 months|The proportion of patients with histologic regression, defined as LSIL or normal histology, at 6 months after first treatment., The proportion of patients with histologic regression, defined as LSIL or normal histology, at 6 months after first treatment., 6 months
To evaluate the efficacy and safety of Cevira速 compared to placebo in treatment of patients with cervical histologic HSIL.A total of 384 subjects will be enrolled globally, among which, 300 subjects of them will be enrolled in China.